

Iron Deficiency Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/IA1C9756E81FEN.html>

Date: March 2022

Pages: 67

Price: US\$ 2,000.00 (Single User License)

ID: IA1C9756E81FEN

Abstracts

Iron Deficiency Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Iron Deficiency Anemia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Iron Deficiency Anemia (Hematological Disorders) pipeline landscape.

Anemia is a condition in which the body does not have enough healthy red blood cells. Iron helps make red blood cells. When body does not have enough iron, it will make fewer red blood cells or red blood cells that are too small. This is called iron deficiency anemia. Symptoms include feeling grumpy, headaches and problems concentrating or thinking. Treatment includes iron supplements and eating iron-rich foods.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Iron Deficiency Anemia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and

development history and latest news and press releases.

The Iron Deficiency Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 3, 2 and 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Iron Deficiency Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Iron Deficiency Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Iron Deficiency Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Iron Deficiency Anemia (Hematological Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Iron Deficiency Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Iron Deficiency Anemia - Overview

Iron Deficiency Anemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Iron Deficiency Anemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Iron Deficiency Anemia - Companies Involved in Therapeutics Development

Akebia Therapeutics Inc

Disc Medicine Inc

Entrinsic Bioscience Inc

Iron4u Aps

Jiangsu Aosaikang Pharmaceutical Co Ltd

Keros Therapeutics Inc

Nemysis Ltd

Novartis AG

Pharmacosmos AS

Renibus Therapeutics Inc

Rockwell Medical Inc

Shield Therapeutics Plc

Vifor Pharma Ltd

Iron Deficiency Anemia - Drug Profiles

AKB-5343 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CSJ-137 - Drug Profile

Product Description

Mechanism Of Action

History of Events

DISC-0974 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Ferric bepectate - Drug Profile

Product Description

Mechanism Of Action

History of Events

ferric carboxymaltose - Drug Profile

Product Description

Mechanism Of Action

History of Events

ferric carboxymaltose - Drug Profile

Product Description

Mechanism Of Action

ferric derisomaltose - Drug Profile

Product Description

Mechanism Of Action

History of Events

ferric maltol - Drug Profile

Product Description

Mechanism Of Action

History of Events

ferric pyrophosphate citrate - Drug Profile

Product Description

Mechanism Of Action

History of Events

hinokitiol - Drug Profile

Product Description

Mechanism Of Action

IHAT-02 - Drug Profile

Product Description

Mechanism Of Action

History of Events

iron sucrose - Drug Profile

Product Description

Mechanism Of Action

History of Events

KER-047 - Drug Profile

Product Description

Mechanism Of Action

History of Events

KTI-016 - Drug Profile

Product Description

Mechanism Of Action

KTI-018 - Drug Profile

Product Description

Mechanism Of Action

KTI-2338 - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody 1 to Inhibit Hemojuvelin for Chronic Inflammation and Hematological Disorders - Drug Profile

Product Description

Mechanism Of Action

History of Events

PT-30 - Drug Profile

Product Description

Mechanism Of Action

History of Events

VS-007 - Drug Profile

Product Description

Mechanism Of Action

Iron Deficiency Anemia - Dormant Projects

Iron Deficiency Anemia - Discontinued Products

Iron Deficiency Anemia - Product Development Milestones

Featured News & Press Releases

Feb 04, 2022: Shield Therapeutics: Innovation in iron deficiency treatment with a focus on clinical utility of Accrufer/Feraccru

Dec 20, 2021: Vifor Pharma and American Regent announce settlement of Injectafer patent litigation

Dec 16, 2021: Shield Therapeutics: Patient access expands for Accrufer

Dec 16, 2021: Injectafer (ferric carboxymaltose injection) receives FDA approval for the treatment of pediatric patients with iron deficiency anemia

Dec 14, 2021: Rockwell Medical receives important feedback from FDA on its IND application for phase 2 trial of ferric pyrophosphate citrate in home infusion

Nov 16, 2021: Rockwell Medical study demonstrates no drug-drug interaction between ferric pyrophosphate citrate and unfractionated heparin

Nov 11, 2021: Rockwell Medical submits investigational new drug application with FDA for its proposed clinical trial of FPC as a treatment for iron deficiency anemia in patients receiving home infusion

Nov 04, 2021: Rockwell Medical presents Triferic real world evidence update at ASN Kidney Week 2021

Aug 31, 2021: Vifor Pharma's Ferinject granted new recommendations in updated 2021 ESC heart failure guidelines

Aug 09, 2021: Shield Therapeutics: AEGIS-CKD study results published in AJKD

Jun 28, 2021: Rockwell Medical files pre-IND meeting request with FDA for its proposed clinical trial of FPC as a treatment for iron deficiency anemia in patients receiving home infusion

Jun 24, 2021: Shield Therapeutics: US launch of Accrufer confirmed for July 1, 2021

May 21, 2021: Shield Therapeutics: US update

May 18, 2021: Shield Therapeutics: AEGIS-H2H study results published in Inflammatory Bowel Diseases

May 12, 2021: Nemysis announces grant of first Chinese patent for IHAT

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Iron Deficiency Anemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Iron Deficiency Anemia - Pipeline by Akebia Therapeutics Inc, 2022
Iron Deficiency Anemia - Pipeline by Disc Medicine Inc, 2022
Iron Deficiency Anemia - Pipeline by Entrinsic Bioscience Inc, 2022
Iron Deficiency Anemia - Pipeline by Iron4u Aps, 2022
Iron Deficiency Anemia - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2022
Iron Deficiency Anemia - Pipeline by Keros Therapeutics Inc, 2022
Iron Deficiency Anemia - Pipeline by Nemysis Ltd, 2022
Iron Deficiency Anemia - Pipeline by Novartis AG, 2022
Iron Deficiency Anemia - Pipeline by Pharmacosmos AS, 2022
Iron Deficiency Anemia - Pipeline by Renibus Therapeutics Inc, 2022
Iron Deficiency Anemia - Pipeline by Rockwell Medical Inc, 2022
Iron Deficiency Anemia - Pipeline by Shield Therapeutics Plc, 2022
Iron Deficiency Anemia - Pipeline by Vifor Pharma Ltd, 2022
Iron Deficiency Anemia - Dormant Projects, 2022
Iron Deficiency Anemia - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Iron Deficiency Anemia, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Iron Deficiency Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/IA1C9756E81FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IA1C9756E81FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

